###begin article-title 0
###xml 50 53 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
Type I interferon-dependent gene MxA in perinatal HIV-infected patients under antiretroviral therapy as marker for therapy failure and blood plasmacytoid dendritic cells depletion
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 261 263 261 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 57 60 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 258 261 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 263 271 <span type="species:ncbi:9606">patients</span>
To determine the role of interferon-alpha in controlling HIV infection we phenotypically and functionally analyzed circulating plasmacytoid dendritic cells (pDC), which are known to be the highest interferon-alpha producing cells, in 33 perinatally infected HIV+ patients undergoing standard antiretroviral therapy.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
Circulating pDC were identified by flow cytometry using anti-BDCA-2 monoclonal antibody and by measuring BDCA-2 mRNA by real-time PCR, while tissue-resident pDC were identified by immunohistochemistry. mRNA for interferon-alpha and MxA, a gene that is specifically induced by interferon-alpha, was quantified in peripheral blood cells by real-time PCR, while serum interferon-alpha protein was measured by ELISA.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 298 300 298 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 512 514 512 514 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 176 179 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 189 197 <span type="species:ncbi:9606">patients</span>
###xml 222 230 <span type="species:ncbi:9606">patients</span>
###xml 446 449 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 483 491 <span type="species:ncbi:9606">patients</span>
While median values of pDC, both in terms of percentage and absolute number, were not statistically different from age-matched controls, interferon-alpha mRNA was increased in HIV-infected patients. However, in a group of patients with long disease duration, having a low number of both pDC and CD4+ lymphocytes and a significant increase of serum interferon-alpha, MxA mRNA was produced at high level and its expression directly correlated with HIV RNA copy numbers. Furthermore in patients displaying a low CD4+ blood cell count, a severe depletion of pDC in the tonsils could be documented.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
###xml 314 317 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 318 326 <span type="species:ncbi:9606">patients</span>
HIV replication unresponsive to antiretroviral treatment in perinatal-infected patients with advanced disease and pDC depletion may lead to interferon-alpha expression and subsequent induction of MxA mRNA. Thus, the latter measurement may represent a valuable marker to monitor the clinical response to therapy in HIV patients.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 159 160 159 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 161 162 161 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 294 295 294 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 627 629 627 629 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 955 956 955 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 957 958 957 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1097 1099 1094 1096 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1297 1298 1294 1295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1299 1300 1296 1297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1405 1406 1402 1403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 66 69 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 79 87 <span type="species:ncbi:9606">children</span>
###xml 344 352 <span type="species:ncbi:9606">children</span>
###xml 564 567 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 576 584 <span type="species:ncbi:9606">children</span>
###xml 636 644 <span type="species:ncbi:9606">children</span>
###xml 650 653 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Over the last 10 years the use of antiretroviral therapy (ART) in HIV-infected children has resulted in noticeable benefit as indicated by increased survival [1,2]. However, poor adherence to prescriptions and the high rates of virus replication that are characteristic of perinatal infection [3] often lead to higher virological set points in children compared to adults and lower rates of attainment of undetectable viral loads. Therefore, the identification of immunological correlates of immune reconstitution and early predictors of antiretroviral failure in HIV-treated children are needed. Concomitantly with loss of CD4+ cells, children with HIV infection display a profound impairment of the innate branch of immune system as indicated by the progressive decrease of circulating dendritic cells (DC). DC are a heterogeneous population of antigen-presenting cells that are required to draw the first line of host defense against viral infections [4-6]. Two subsets of DC were originally identified in peripheral blood on the basis of the beta2-integrin expression (CD11c marker): the CD11c+ myeloid DC (mDC) and the CD11c- plasmacytoid DC (pDC). DC phenotype is defined on the basis of the two monoclonal antibodies (mAb) BDCA-1 and BDCA-2, which identify blood mDC and pDC, respectively [7,8]. But, BDCA-1 is also expressed on monocytes and is not sufficient by itself to define dendritic cells [8].
###end p 11
###begin p 12
###xml 313 314 309 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 315 317 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 595 597 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 598 600 590 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 899 901 883 885 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 914 916 898 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 917 919 901 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 930 932 914 916 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1129 1131 1113 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1132 1134 1116 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1294 1296 1278 1280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1297 1299 1281 1283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1300 1302 1284 1286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1303 1305 1287 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 357 360 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 590 593 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 738 741 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 987 990 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1057 1060 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1104 1109 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1119 1127 <span type="species:ncbi:9606">patients</span>
Although blood DC represent less than 1% of total peripheral blood mononuclear cells (PBMC), they exert a relevant protective role against invading pathogens by producing IL-12 and interpheron-alpha (IFN-alpha) and by inducing T-cell immunity via presentation of pathogen-specific antigens on their cell surface [9-13]. IFN-alpha has been shown to decrease HIV replication by induction of IFN-stimulated genes. One such gene is Myxovirus resistance 1, which encodes for the Myxovirus resistance protein A (MxA), a protein capable of inhibiting the replication of several viruses, including HIV [14,15]. However, it is controversial whether the increase of IFN-alpha secretion, which is observed during disease progression, contributes to HIV pathogenesis. It has been described that high levels of IFN-alpha might exert deleterious effects on the immune cells by inducing depletion of uninfected CD4+ lymphocytes [16-18]. Like CD4+ cells, DC express the receptor machinery necessary for HIV entry, and therefore are vulnerable to the detrimental effects of HIV infection and are functionally impaired in HIV-1-infected patients [19-24]. Furthermore, pDC loss is believed to be a predictor of disease progression, of increased risk of opportunistic infections and of Kaposi sarcoma development [19,20,23,24].
###end p 12
###begin p 13
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 308 310 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 203 211 <span type="species:ncbi:9606">children</span>
It is known that immune reconstitution after ART is mostly due to newly released lymphocytes from the thymus [25]. However, at the same time, antiretroviral regimens influence DC pool in both adults and children by completely restoring mDC and only partially recovering the frequency and function of pDC [21,26].
###end p 13
###begin p 14
###xml 221 223 217 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 87 90 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 100 108 <span type="species:ncbi:9606">patients</span>
In this study we evaluated pDC and IFN-alpha involvement in a cohort of 33 perinatally HIV-infected patients undergoing ART at various stages of immune-reconstitution, as determined by analysis of their viral load and CD4+ T-cell counts.
###end p 14
###begin title 15
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and methods
###end title 15
###begin title 16
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and controls
###end title 16
###begin p 17
###xml 110 115 <span type="species:ncbi:9606">human</span>
###xml 188 191 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 316 324 <span type="species:ncbi:9606">Patients</span>
Informed consent was obtained, in accordance with institutional review board guidelines for the protection of human subjects, from parents or legal guardians of 33 subjects with perinatal HIV infection (age: from 2 up to 19 years), and from 15 age-matched healthy controls (mean age: 11.8 years, range: 2-19 years). Patients with acute infectious diseases or opportunistic infections at the time of the analysis were excluded from the study.
###end p 17
###begin title 18
Circulating pDC and serum IFN-alpha levels determination
###end title 18
###begin p 19
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
The identification of pDC was performed using Blood Dendritic Cell enumeration Kit (Miltenyi Biotec GmbH, Bergish Gladbach, Germany) as previously described [27]. Blood samples were stained simultaneously with anti-BDCA-2-FITC mAb to identify pDC, anti-CD19-PE-Cy5 and anti-CD14-PE-Cy5 mAbs to exclude B cells and monocytes, and with a fluorescent cell-impermeant dye (Dead cells Discriminator), which binds covalently and irreversibly to nucleic acids of dead cells. After cells staining, erythrocytes were lysed with ammonium chloride buffer (Red Blood Cell Lysis), and cells were washed and fixed using formaldehyde (Fix Solution). Finally, cells were analyzed by 3-color flow cytometry using FACScan (Becton Dickinson, San Jose, CA, USA).
###end p 19
###begin p 20
The level of IFN-alpha in the serum was measured by Sandwich ELISA using an IFN-alpha kit (PBL Biomedical Laboratories, Piscataway, NJ, USA) and following the manufacturer's instructions.
###end p 20
###begin title 21
IFN-alpha, BDCA-2, MxA and TRECs quantification by real-time PCR
###end title 21
###begin p 22
###xml 200 209 200 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1039 1041 1034 1036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1163 1165 1158 1160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 28 36 <span type="species:ncbi:9606">patients</span>
Blood samples (2.5 ml) from patients and controls were drawn into PAXgene tubes (preAnalytiX GmbH, Hombrechtikon, CH), which contain an additive that stabilizes gene transcription profile by reducing in vitro RNA degradation and minimizing gene induction. RNA was prepared using PAXgene Blood RNA kit following manufacturer's instructions (preAnalytiX). To remove contaminating DNA, samples were treated with DNase (Qiagen Inc. Valencia, CA, USA). Five hundred ng of total RNA were reverse transcribed with random hexamers in a final volume of 20 mul using the TaqMan RT kit (Applied Biosystems, Foster City, CA, USA). Real-time PCR analysis was performed with the GeneAmp 5700 Sequence Detection System (Applied Biosystems). For IFN-alpha and BDCA-2 mRNA measure a pre-developed TaqMan assay, which included the appropriate primer/probe combination, was purchased from Applied Biosystems and the test was performed following manufacturer's instructions. For MxA mRNA quantification we used primers and probes described by Pachner et al. [28]; the experiments were performed after standardization of the assay in terms of precision, accuracy and reproducibility [29]. All PCR reactions were set up in 96-well optical reaction plates (ABgene, Epsom, UK) in a final volume of 25 mul with 12.5 mul of double concentrated TaqMan universal PCR Master mix (Applied Biosystems), 3 mul of cDNA, 1.25 mul of primer/probe mix for IFN-alpha and BDCA-2 and 600 nM of primers and 200 nM of probe for MxA. Probe and primer concentration for the housekeeping gene, Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), were respectively 400 and 200 nM. PCR amplification started with a first step at 50degreesC for 2 min., followed by an initial heating at 95degreesC for 10 min.; samples were then subjected to 45 cycles of denaturation at 95degreesC for 15 sec and annealing at 60degreesC for 1 min. Each sample was run in duplicate.
###end p 22
###begin p 23
###xml 202 217 198 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-&#916;&#916;CtCt</sup>
The relative quantification of BDCA-2, IFN-alpha and MxA mRNA expression was calculated using the Comparative cycle threshold (Ct) method according to the following formula: Normalization Ratio (NR) = 2-DeltaDeltaCtCt. First, for each sample, DeltaCt value was calculated as the Ct of the target gene minus the Ct of GAPDH and then the DeltaDeltaCt value was obtained as the difference between the DeltaCt of the sample and the DeltaCt of the calibrator. According to the formula, the normalization ratio of the calibrator in each run is 1. As calibrator in each sample run, we utilized the same RNA extracted from a single healthy control, and stored at -80degreesC.
###end p 23
###begin p 24
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
The quantification of the signal-joint T-cell receptor excision circles (TRECs) was performed on PBMC separated by Ficoll-Hypaque density gradient centrifugation using the standard curve method described by Pirovano et al. [30].
###end p 24
###begin title 25
Immunohistochemistry
###end title 25
###begin p 26
###xml 420 421 420 421 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 422 424 422 424 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 902 903 902 903 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1025 1026 1025 1026 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
###xml 53 56 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 241 246 <span type="species:ncbi:10090">mouse</span>
Lymph node and tonsil specimens from 8 patients with HIV infection and from 2 age-matched controls were analyzed. Each specimen was fixed in buffered formalin and embedded in paraffin. Sections were stained overnight with a dilution 1:50 of mouse anti-CD123 mAb (clone 7G3, IgG2a, Becton Dickinson PharMingen Biosciences Europe, Erembodegem-AALST, Belgium), after inhibition of endogenous peroxidase activity with 0.3% H2O2 in methanol for 20 min and heat-induced epitope retrieval in Tris-EDTA buffer (pH 9.0). Reaction was developed with the polymer peroxidase conjugated technique (ChemMate, Dako, Glostrup, DK) and diaminobenzydine as chromogen. Sections were counterstained with haematoxylin. Cell counting was performed using an Olympus BX60 microscope equipped with the Olympus DP-70 digital camera and the Olympus Soft Imaging System Cell-F 2.5; two medium-power fields (corresponding to 0.3 mm2), selected on the basis of highest content of positive cells, were evaluated and values were expressed as mean per one mm2.
###end p 26
###begin title 27
Statistical analysis
###end title 27
###begin p 28
###xml 192 200 <span type="species:ncbi:9606">patients</span>
Since real-time PCR data did not follow a Gaussian distribution, results were expressed as median and range and analyzed using nonparametric statistical tests. Differences between values from patients and controls were examined by Mann-Whitney test, while comparisons between more than 2 groups of results were assessed by Kruskal-Wallis ANOVA. In case of significance, Dunn's multiple columns post-test was applied to compare the sub-groups of treatment. Moreover, Spearman's correlation test was used to find an association between variables. Two-tailed P values < 0.05 were considered to be statistically significant.
###end p 28
###begin title 29
Results
###end title 29
###begin title 30
###xml 44 47 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Clinical and immune features of perinatally HIV- infected patients
###end title 30
###begin p 31
###xml 133 135 133 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 200 201 200 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 294 295 294 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 359 361 357 359 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 510 512 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 666 668 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1117 1118 1115 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1520 1521 1518 1519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1522 1523 1520 1521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 71 74 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
###xml 327 335 <span type="species:ncbi:9606">patients</span>
###xml 483 486 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 500 508 <span type="species:ncbi:9606">children</span>
###xml 683 691 <span type="species:ncbi:9606">patients</span>
###xml 768 776 <span type="species:ncbi:9606">patients</span>
###xml 865 873 <span type="species:ncbi:9606">patients</span>
###xml 1101 1109 <span type="species:ncbi:9606">patients</span>
###xml 1269 1277 <span type="species:ncbi:9606">children</span>
###xml 1341 1349 <span type="species:ncbi:9606">patients</span>
###xml 1421 1429 <span type="species:ncbi:9606">children</span>
We evaluated pDC number and function in a population of 33 perinatally HIV-infected patients, 17 of them were female and 16 male. CD4+ T lymphocytes ranged from 18.6% to 43.4% (median of 31.6%; Table 1). In particular, 26 of 33 subjects showed an adequate immune reconstitution (Category 1, CD4+% >/= 25%), while the remaining patients had a low number of CD4+ and a high viral load. They all were under ART at the time of the analysis according to PENTA guidelines for treatment of HIV infection in children [31], but the adopted treatment regimen varied from subject to subject depending on the pattern of genotypic resistance and on the adherence to the therapy [32]. Twenty-four patients were subjected to ART regimen containing at least one protease inhibitor, 7 patients were treated with a non-nucleoside reverse transcriptase inhibitor, and the remaining 2 patients with two nucleoside reverse transcriptase inhibitors because of their poor adherence to other regimens. Despite the adoption of ART, complete suppression of viral load (less than 50 copies/ml) was achieved only in 18 out of 33 patients (Table 1). This unsatisfactory result was probably the consequence of several contributing reasons, including the common observance of genotypic resistance in children failing the treatment, the long length of the disease in older patients, the slow reduction of viral load following the introduction of ART in children, and possibly, the difficulty in obtaining long-term adherence to therapy in adolescents [2,3].
###end p 31
###begin p 32
###xml 39 42 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 52 60 <span type="species:ncbi:9606">children</span>
Clinical and immunological features of HIV-infected children
###end p 32
###begin p 33
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 15 18 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
aChildren with HCV co-infection
###end p 33
###begin title 34
###xml 7 10 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 32 35 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
pDC in HIV-infected perinatally HIV-infected patients
###end title 34
###begin p 35
###xml 145 146 145 146 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 150 151 150 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 155 157 155 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 383 385 383 385 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 564 566 562 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 606 608 604 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 672 674 670 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 724 726 722 724 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 776 778 774 776 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 969 971 967 969 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1096 1098 1094 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 67 70 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 80 88 <span type="species:ncbi:9606">patients</span>
###xml 721 724 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 726 734 <span type="species:ncbi:9606">children</span>
###xml 966 969 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 971 979 <span type="species:ncbi:9606">patients</span>
We evaluated both the proportion and the absolute number of pDC in HIV-infected patients by using an assay that selectively identified the BDCA-2+CD14-CD19- cell subset. As observed in healthy controls [33], there is an inverse correlation (r = -0.503, p = 0.003) of pDC values with age (Figure 1A) and a direct correlation (r = 0.537; p = 0.002) with the absolute cell number of CD4+ T lymphocytes (Figure 1B). The progressive decline of pDC (values ranging from 33,300 cells/mul to 3,402 cells/mul) can reflect the "natural" decline in pDC counts during ageing [33] and is related to the reduction of CD4+ cell number. This is in agreement with data from Azzoni et al. [34], demonstrating a greater depletion of pDC in HIV+ children with a clinical history of decreasing CD4+ cell percentage. Median values of pDC, both in terms of percentage and absolute number, are not statistically different from those measured in age-matched controls, although pDC number of HIV+ patients receiving ART is heterogeneous and varies from extremely low blood counts up to levels observed in controls (Figure 1C).
###end p 35
###begin p 36
###xml 48 50 48 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 80 82 80 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 0 95 0 95 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) Correlation of pDC with age and (B) with CD4<sup>+ </sup>cell number in ART-treated HIV<sup>+ </sup>patients. (C)</bold>
###xml 143 145 143 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 190 193 190 193 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(D)</bold>
###xml 295 297 291 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 77 80 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
###xml 140 143 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 145 153 <span type="species:ncbi:9606">children</span>
###xml 292 295 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 297 305 <span type="species:ncbi:9606">children</span>
(A) Correlation of pDC with age and (B) with CD4+ cell number in ART-treated HIV+ patients. (C) Percentage and number of pDC in ART-treated HIV+ children and in age-matched controls (CTRL). (D) Values of IFN-alpha mRNA, obtained by real-time PCR and expressed as normalization ratio (NR), in HIV+ children and CTRL.
###end p 36
###begin p 37
###xml 65 66 65 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 222 224 222 224 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 163 171 <span type="species:ncbi:9606">patients</span>
###xml 219 222 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 224 232 <span type="species:ncbi:9606">patients</span>
###xml 253 261 <span type="species:ncbi:9606">children</span>
###xml 379 387 <span type="species:ncbi:9606">patients</span>
Since BDCA-2 was shown to be modulated following pDC activation [7], we have evaluated the amount of BDCA-2 mRNA by real-time PCR. Comparable values were found in patients and healthy controls (median value of: 1.13 in HIV+ patients vs. 0.93 in healthy children, p = NS), thus confirming the data obtained by cytofluorimetry. We did not assess pDC counts before treatment in our patients, but based on previous observations we speculate that pDC counts, possibly lower before treatment, might be increased after starting the ART.
###end p 37
###begin title 38
###xml 40 43 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
IFN-alpha and MxA mRNA induction during HIV infection
###end title 38
###begin p 39
###xml 325 327 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1D</xref>
###xml 561 563 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 564 566 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 803 805 787 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 978 979 958 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1033 1035 1013 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1036 1038 1016 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1039 1041 1019 1021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1186 1188 1166 1168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 1407 1409 1387 1389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 1522 1525 1502 1505 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 1803 1805 1783 1785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 1866 1868 1842 1844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 2113 2115 2085 2087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 2238 2240 2210 2212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 2259 2261 2231 2233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 2337 2339 2309 2311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3D</xref>
###xml 2383 2385 2355 2357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 2386 2388 2358 2360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 2537 2539 2509 2511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 2598 2600 2570 2572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 2868 2870 2840 2842 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 2922 2923 2894 2895 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 3068 3070 3040 3042 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 3122 3124 3094 3096 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 136 139 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 255 258 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 268 276 <span type="species:ncbi:9606">patients</span>
###xml 631 634 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 644 652 <span type="species:ncbi:9606">patients</span>
###xml 667 670 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 755 758 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 773 776 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 786 794 <span type="species:ncbi:9606">patients</span>
###xml 1067 1075 <span type="species:ncbi:9606">patients</span>
###xml 1275 1283 <span type="species:ncbi:9606">patients</span>
###xml 1447 1455 <span type="species:ncbi:9606">patients</span>
###xml 1711 1719 <span type="species:ncbi:9606">patients</span>
###xml 1977 1985 <span type="species:ncbi:9606">children</span>
###xml 2089 2092 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2155 2163 <span type="species:ncbi:9606">children</span>
###xml 2272 2280 <span type="species:ncbi:9606">children</span>
###xml 2472 2475 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2801 2804 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2814 2822 <span type="species:ncbi:9606">patients</span>
###xml 2990 2998 <span type="species:ncbi:9606">patients</span>
Since pDC are specialized cells that produce large amounts of IFN-alpha in response to viral infections, we sought to determine whether HIV infection induces the expression of this cytokine. We observed a significant increase of IFN-alpha mRNA in PBMC in HIV-infected patients as compared to healthy control subjects (Figure 1D), suggesting that the chronic infection induces IFN-alpha production. Next, we analyzed the expression of MxA mRNA, which is selectively induced after type-I IFN receptor binding and is a marker for cell responsiveness to IFN-alpha [14,35]. We found that MxA mRNA levels were significantly increased in HIV-infected patients with abnormal HIV viral load RNA. Indeed, we observed a direct correlation between MxA expression and HIV RNA copies in HIV infected patients (Figure 2B), suggesting that a high number of viral copies may directly influence the induction of MxA mRNA. Due to the fact that pDC are one of the principal producers of IFN-alpha [9] and that MxA is a marker of type I IFN bioactivity [29,35,36], one might predict that patients with the largest number of circulating pDC might express more MxA as compared to age-matched controls (Figure 2A). On the contrary, we have observed that higher levels of MxA mRNA are found in those patients with lower number of circulating pDC, as indicated by the strong negative correlation between these two parameters (Figure 2C). In particular, we observed that 15 patients displayed MxA mRNA levels above the cut-off, established as the 99th percentile of the distribution of MxA in healthy control subjects (NR = 2.7, shown as dotted line in the figure), while the remaining presented normal MxA mRNA expression. Surprisingly, patients with MxA mRNA levels above the cut-off are those with lower numbers of pDC (Figure 3A) and significantly higher serum levels of IFN-alpha (Figure 3B). It is of note that the median level of this cytokine is low in both groups, at levels observed in control children, but it has been demonstrated that circulating IFN-alpha is elevated in the sera just at the moment of HIV antigen appearance [37]. Moreover, we have also observed that children with low MxA mRNA (<2.7) below the cut-off show an increased number of CD4+ lymphocyte (Figure 3C) and that children with increased MxA mRNA (>2.7) are of older age (Figure 3D). Since MxA levels do not vary among ages [29,36], we speculate that increased levels of MxA mRNA are associated with the length of HIV infection. Finally, since pDC are present within the thymus [15] and immune-reconstitution is related to thymic function [38], we utilized real-time PCR to determine the levels of DNA episomes created in the thymus during T-cell receptor rearrangement process, known as TRECS. We observed that TREC values were comparable in HIV-infected patients and age-matched controls (63,345 TRECs/1 x 106 cells, range: 39,470-173,194 vs. 54,560 TRECs/1 x 106, range: 7,279-299,500), without any detectable difference between patients with normal or increased MxA mRNA values (median: 65,925 TRECs/1 x 106 cells, range: 15,259-155,003 vs. 51,125 TRECs/1 x 106 cells, range: 17,586-128,900). Similarly, there was no significant correlation between TRECs and pDC cell number (data not shown).
###end p 39
###begin p 40
###xml 38 40 38 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 0 69 0 69 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) MxA mRNA levels in ART-treated HIV<sup>+ </sup>children and controls (CTRL).</bold>
###xml 125 128 125 128 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B)</bold>
###xml 144 147 144 147 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(C)</bold>
###xml 35 38 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 40 48 <span type="species:ncbi:9606">children</span>
###xml 110 113 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
(A) MxA mRNA levels in ART-treated HIV+ children and controls (CTRL). Correlation between MxA mRNA levels and HIV viral load (B) and pDC number (C). NR: normalization ratio.
###end p 40
###begin p 41
###xml 55 57 55 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 0 195 0 195 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Immunological parameters of 2 groups of ART-treated HIV<sup>+ </sup>patients divided according the production of MxA mRNA in MxA-non induced (cut-off value NR &lt; 2.7) and MxA-induced (NR &gt; 2.7) patients. (A)</bold>
###xml 211 214 211 214 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B)</bold>
###xml 241 244 237 240 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(C)</bold>
###xml 258 260 254 256 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 277 280 273 276 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(D)</bold>
###xml 52 55 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 57 65 <span type="species:ncbi:9606">patients</span>
###xml 182 190 <span type="species:ncbi:9606">patients</span>
###xml 292 300 <span type="species:ncbi:9606">patients</span>
Immunological parameters of 2 groups of ART-treated HIV+ patients divided according the production of MxA mRNA in MxA-non induced (cut-off value NR < 2.7) and MxA-induced (NR > 2.7) patients. (A) Number of pDC, (B) level of serum IFN-alpha, (C) number of CD4+ lymphocytes, and (D) age of the patients. NR: normalization ratio.
###end p 41
###begin title 42
###xml 27 30 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 40 48 <span type="species:ncbi:9606">children</span>
pDC in lymphoid tissues of HIV infected children
###end title 42
###begin p 43
###xml 65 67 65 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 229 231 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 289 291 285 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 716 718 712 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 727 729 723 725 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 783 785 779 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 861 863 857 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
###xml 1059 1061 1055 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
###xml 1183 1185 1179 1181 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1313 1315 1309 1311 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1388 1390 1384 1386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4D</xref>
###xml 125 133 <span type="species:ncbi:9606">children</span>
###xml 148 151 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 389 392 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 402 410 <span type="species:ncbi:9606">children</span>
###xml 464 467 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 477 485 <span type="species:ncbi:9606">children</span>
###xml 724 727 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 729 737 <span type="species:ncbi:9606">patients</span>
###xml 803 806 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 816 824 <span type="species:ncbi:9606">children</span>
###xml 1132 1135 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1145 1153 <span type="species:ncbi:9606">children</span>
###xml 1200 1203 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1365 1368 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The decline of circulating pDC, correlating with reduction of CD4+ and increased IFN-alpha-dependent MxA gene expression, in children with advanced HIV infection suggests that pDC might accumulate in secondary lymphatic tissues [39]. Thus we sought to determine if pDC (identified as CD123+ cells) are present in lymph nodes and tonsils, previously obtained for diagnostic purposes from 8 HIV-infected children. The number of pDC identified in lymphoid tissues of HIV-infected children was extremely variable: in some specimens the pDC were abundant in the interfollicular areas of tonsils and lymph nodes of both age-matched control subjects (a section of tonsil tissue is shown as representative example in Figure 4A) and HIV+ patients (a representative example is shown in Figure 4B), while in other HIV-infected children they were severely depleted (Figure 4C). It should be noted that pDC were regularly scant in cases showing general lymphoid depletion, but they are found to be rare also in cases with preserved lymphoid tissue, as indicated in Figure 4C. After plotting the number of pDC detected in lymphoid tissues of the HIV-infected children against the percentage of CD4+ or against the HIV-RNA copy number, we observed a direct correlation between the number of lymphatic tissue-resident pDC and CD4+ blood counts, while there was no correlation with HIV viral load (Figure 4D).
###end p 43
###begin p 44
###xml 0 23 0 23 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Analysis of tissue pDC.</bold>
###xml 397 398 397 398 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 523 524 523 524 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 744 746 744 746 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 796 798 796 798 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 849 851 849 851 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 610 615 <span type="species:ncbi:9606">child</span>
###xml 620 623 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 633 638 <span type="species:ncbi:9606">child</span>
###xml 663 666 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 676 681 <span type="species:ncbi:9606">child</span>
###xml 821 824 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 846 849 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 851 859 <span type="species:ncbi:9606">children</span>
Analysis of tissue pDC. pDC counting was performed using an Olympus BX60 microscope equipped with the Olympus DP-70 digital camera and the Olympus Soft Imaging System Cell-F 2.5. Sections were stained with anti-CD123 by immunoperoxidase technique and counterstained with Mayer's hematoxylin. Magnifications: x100 (left panels), x500 (right panels). Two medium-power fields (corresponding to 0.3 mm2), selected on the basis of highest content of CD123+ positive cells, were evaluated and values were expressed as mean per mm2. Panels A, B and C respectively show tonsil sections from one representative healthy child, an HIV-infected child with abundant pDC and a HIV-infected child showing pDC depletion. In panel D are the number of pDC (CD123+ cells) of tonsil specimens plotted against the CD4+ cell percentage or the HIV RNA copy number of 8 HIV+ children.
###end p 44
###begin title 45
Discussion
###end title 45
###begin p 46
###xml 36 38 36 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 516 518 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 906 908 906 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 100 103 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 414 417 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The relationship between pDC and CD4+ cells is based on numerous concordant observations. Following HIV infection, both cell subsets decrease to levels associated with increased susceptibility to opportunistic infections [24]. Due to the fact that pDC infiltrate the medulla and the corticomedullary junction of the thymus, where they inhibit the replication of the virus [15], and due to the relationship between HIV infection and the release of newly generated T lymphocytes from the thymus into peripheral blood [26], we determined whether there was a direct relationship between the number of pDC and the extent of thymic output. We did not observe a correlation between the number of newly produced T lymphocytes containing TRECs and the number of pDC, most likely due to the fact that lymphocyte homeostasis is also regulated in peripheral lymphoid organs, depending on cell replication and removal [40].
###end p 46
###begin p 47
###xml 66 68 66 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 298 300 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 108 111 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Although higher pDC frequency found in long-term non-progressors [41] indicate that pDC also have a role in HIV infection control, a possible link also exists between disease outcome and reduced pDC number and function, including a decreased production of IFN-alpha by pDC during AIDS progression [24].
###end p 47
###begin p 48
###xml 76 78 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 207 209 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 210 212 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 603 605 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 733 735 713 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 736 738 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1104 1106 1076 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1269 1271 1241 1243 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1660 1662 1632 1634 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 61 64 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 128 131 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 270 273 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 283 291 <span type="species:ncbi:9606">children</span>
###xml 552 555 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1208 1211 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1221 1229 <span type="species:ncbi:9606">patients</span>
###xml 1466 1469 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1479 1487 <span type="species:ncbi:9606">children</span>
###xml 1639 1647 <span type="species:ncbi:9606">children</span>
###xml 1825 1828 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1838 1846 <span type="species:ncbi:9606">children</span>
###xml 1897 1905 <span type="species:ncbi:9606">patients</span>
High plasma levels of IFN-alpha can be detected during acute HIV infection [42], but it is usually barely detectable in chronic HIV infection due to its short half-life or the rapid binding to its receptor [43-45]. Accordingly, we found low serum levels of IFN-alpha in HIV-infected children, but we detected significantly increased levels of IFN-alpha mRNA in blood cells, suggesting that pDC were in an active state and potentially capable to deliver the cytokine. The measurement of serum IFN-alpha and/or IFN-alpha mRNA might be used as markers of HIV disease progression and/or of therapy failure [42]. However, the biochemical and biological properties of the cytokine, including its limited distribution to blood circulation [17,44], present a serious limitation for its use in a clinical setting. On the contrary, the evaluation of MxA expression by real-time PCR might constitute a sensitive and reliable assay for measuring the extent of IFN-alpha biological activity. Since MxA mRNA is induced in response to IFN-alpha, the expression of MxA is strictly related to the amount of the cytokine [36]. Indeed, we have demonstrated that MxA mRNA expression increased above normal levels in ART-treated HIV-infected patients who had low numbers of both pDC and CD4+ cells, suggesting that analysis of MxA induction could serve as a convenient marker for the evaluation of extent of pDC immune-restoration. In particular, MxA mRNA was distinctively increased in HIV-infected children with marked depletion of circulating pDC at levels that were proportional to viral load. This indicates that the failure to reach viral suppression in children with low CD4+ and pDC leads to high increased levels of IFN-alpha. According to this hypothesis, we have observed that serum IFN-alpha concentration was significantly higher in HIV-infected children who have increased MxA mRNA values as compared to patients with MxA expression below the cut-off.
###end p 48
###begin p 49
###xml 433 435 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 535 537 524 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 657 662 646 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 665 667 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1077 1082 1066 1071 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 1085 1087 1074 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 1221 1223 1210 1212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1360 1362 1349 1351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 39 42 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 416 421 <span type="species:ncbi:9606">human</span>
###xml 475 478 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 986 989 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 999 1007 <span type="species:ncbi:9606">patients</span>
###xml 1218 1221 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1334 1337 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
We have also observed that perinatally HIV-infected patients with low pDC number displayed the highest levels of MxA mRNA production. We speculate that MxA induction might be influenced by the interaction of IFN receptor with its other ligand, IFN-beta, by an augmented IFN-alpha synthetic activity of fewer circulating pDC, or by the increased production of IFN-alpha by sources other than circulating pDC, such as human monocytes [46] or tissue-resident pDC. Indeed, since HIV infection up-regulates the pDC chemokine receptor CCR7 [47], these cells might accumulate in T-cell rich lymphoid tissues, such as tonsils or lymph nodes. Supporting this Dillon et al. [39] demonstrated an accumulation of partially activated pDC in lymphoid tissues. We did not observe a reduction of circulating pDC, but the immunohistochemistry results appear to argue against the hypothesis that enhanced tissue pDC migration is the main factor explaining the inverse correlation with MxA in perinatally HIV-infected patients. These issues will need further research, considering that Biancotto et al. [48] have demonstrated a reduction of pDC in nodes of chronically infected adults. Further, the number of pDC in lymphatic tissues of HIV+ individuals might depend on the stage of the disease and on the extent of pDC activation and susceptibility to HIV-dependent cell death [39].
###end p 49
###begin p 50
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 298 300 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 301 303 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 67 75 <span type="species:ncbi:9606">patients</span>
###xml 177 180 <span type="species:ncbi:12814?0.7497633322814768|species:ncbi:11886?0.2234143262858946|species:ncbi:12331?0.0041022404544020195">RSV</span>
###xml 204 212 <span type="species:ncbi:9606">patients</span>
###xml 218 221 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 373 381 <span type="species:ncbi:9606">patients</span>
###xml 387 390 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 391 394 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 451 454 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
High levels of MxA have been reported in peripheral blood cells of patients with acute viral infections, including influenza, herpes, cytomegalovirus, rotavirus, adenovirus and RSV [36,49,50], but not in patients with HCV infection, therefore, this virus is considered a poor inducer of IFN-alpha [50,51]. Thus, MxA mRNA levels above the cut-off found in 3 out of 4 of our patients with HIV-HCV co-infection were probably correlated to the outcome of HIV infection.
###end p 50
###begin title 51
Conclusion
###end title 51
###begin p 52
###xml 242 245 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Although the interpretation of an elevated MxA level should be made on the basis of the complete clinical and laboratory data, our results indicate that the analysis of MxA may represent a valuable tool for the management of ART in perinatal HIV infection.
###end p 52
###begin title 53
Competing interests
###end title 53
###begin p 54
The authors declare that they have no competing interests.
###end p 54
###begin title 55
Acknowledgements
###end title 55
###begin p 56
###xml 0 17 0 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Financial Support</italic>
Financial Support. This work was supported by grants from "VI Programma Nazionale di Ricerca sull'AIDS 2006" (Istituto Superiore di Sanita) to LI, PRIN 2007ACZMMZ_005, EU Grant FP7 HLH-cure (project n. 201461) and Fondazione Cariplo NOBEL Grant to RB, and PRIN 2006063183-2006 to FF. FS and CG are supported by "Sovvenzione Globale INGENIO" of Fondo Sociale Europeo, Ministero del Lavoro e della Previdenza Sociale and Regione Lombardia.
###end p 56
###begin article-title 57
###xml 21 24 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 28 36 <span type="species:ncbi:9606">children</span>
Newer treatments for HIV in children
###end article-title 57
###begin article-title 58
###xml 93 98 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 108 116 <span type="species:ncbi:9606">children</span>
Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial)
###end article-title 58
###begin article-title 59
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 18 26 <span type="species:ncbi:9606">children</span>
HIV-1 dynamics in children
###end article-title 59
###begin article-title 60
Dendritic cells and the control of immunity
###end article-title 60
###begin article-title 61
Death, destruction, danger and dendritic cells
###end article-title 61
###begin article-title 62
Dendritic cells: unique leukocyte populations which control the primary immune response
###end article-title 62
###begin article-title 63
BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction
###end article-title 63
###begin article-title 64
The distribution of peripheral blood dendritic cells assayed by a new panel of anti-BDCA monoclonal antibodies in healthy representatives of the polish population
###end article-title 64
###begin article-title 65
IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors
###end article-title 65
###begin article-title 66
Plasmacytoid dendritic cells - virus experts of innate immunity
###end article-title 66
###begin article-title 67
Plasmacytoid dendritic cells in immunity
###end article-title 67
###begin article-title 68
Plasmacytoid dendritic cells: linking innate and adaptive immunity
###end article-title 68
###begin article-title 69
###xml 65 70 <span type="species:ncbi:9606">human</span>
The nature of the principal type 1 interferon-producing cells in human blood
###end article-title 69
###begin article-title 70
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human intracellular Mx-homologous protein is specifically induced by type I interferons
###end article-title 70
###begin article-title 71
###xml 101 106 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Endogenous IFN-alpha production by plasmacytoid dendritic cells exerts an antiviral effect on thymic HIV-1 infection
###end article-title 71
###begin article-title 72
Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS
###end article-title 72
###begin article-title 73
###xml 105 110 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 120 128 <span type="species:ncbi:9606">patients</span>
Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients
###end article-title 73
###begin article-title 74
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 immunopathogenesis: How good interferon turns bad
###end article-title 74
###begin article-title 75
###xml 76 84 <span type="species:ncbi:9606">patients</span>
###xml 90 95 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 122 127 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load
###end article-title 75
###begin article-title 76
###xml 87 92 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection
###end article-title 76
###begin article-title 77
###xml 180 183 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals
###end article-title 77
###begin article-title 78
###xml 104 134 <span type="species:ncbi:11676">human immunodeficiency virus 1</span>
Influence of plasma viremia on defects in number and immunophenotype of blood dendritic cell subsets in human immunodeficiency virus 1-infected individuals
###end article-title 78
###begin article-title 79
###xml 70 73 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients
###end article-title 79
###begin article-title 80
###xml 41 44 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Decreased interferon-alpha production in HIV-infected patients correlates with numerical and functional deficiencies in circulating type 2 dendritic cell precursors
###end article-title 80
###begin article-title 81
###xml 70 105 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 115 123 <span type="species:ncbi:9606">children</span>
Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial
###end article-title 81
###begin article-title 82
###xml 72 77 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 87 95 <span type="species:ncbi:9606">children</span>
Differential restoration of myeloid and plasmacytoid dendritic cells in HIV-1-infected children after treatment with highly active antiretroviral therapy
###end article-title 82
###begin article-title 83
###xml 41 49 <span type="species:ncbi:9606">patients</span>
Functional defects of dendritic cells in patients with CD40 deficiency
###end article-title 83
###begin article-title 84
###xml 78 86 <span type="species:ncbi:9606">patients</span>
MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity
###end article-title 84
###begin article-title 85
###xml 46 54 <span type="species:ncbi:9606">patients</span>
IFNbeta bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays
###end article-title 85
###begin article-title 86
Reconstitution of T-cell compartment after in utero stem cell transplantation: analysis of T-cell repertoire and thymic output
###end article-title 86
###begin article-title 87
PENTA guidelines for the use of antiretroviral therapy, 2004
###end article-title 87
###begin article-title 88
###xml 38 66 <span type="species:ncbi:12721">human immunodeficiency virus</span>
###xml 76 84 <span type="species:ncbi:9606">children</span>
Genotyping for guiding drug choice in human immunodeficiency virus-infected children failing multiple antiretroviral treatment regimens
###end article-title 88
###begin article-title 89
###xml 23 28 <span type="species:ncbi:9606">human</span>
Age-related changes in human blood dendritic cell subpopulations
###end article-title 89
###begin article-title 90
###xml 106 111 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 121 129 <span type="species:ncbi:9606">children</span>
Dendritic and natural killer cell subsets associated with stable or declining CD4+ cell counts in treated HIV-1-infected children
###end article-title 90
###begin article-title 91
###xml 57 62 <span type="species:ncbi:9606">human</span>
cDNA structures and regulation of two interferon-induced human Mx proteins
###end article-title 91
###begin article-title 92
###xml 49 57 <span type="species:ncbi:9606">patients</span>
The MxA protein levels in whole blood lysates of patients with various viral infections
###end article-title 92
###begin article-title 93
###xml 28 31 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 41 49 <span type="species:ncbi:9606">patients</span>
Interferon-alpha in sera of HIV-infected patients
###end article-title 93
###begin article-title 94
###xml 83 86 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Naive CD4(+) T cells and recent thymic emigrant levels in treated individuals with HIV: clinical relevance
###end article-title 94
###begin article-title 95
###xml 135 140 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Plasmacytoid and myeloid dendritic cells with a partial activation phenotype accumulate in lymphoid tissue during asymptomatic chronic HIV-1 infection
###end article-title 95
###begin article-title 96
T cell homeostasis in steady state and lymphopenic conditions
###end article-title 96
###begin article-title 97
###xml 111 116 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Different subsets of peripheral blood dendritic cells show distinct phenotypic and functional abnormalities in HIV-1 infection
###end article-title 97
###begin article-title 98
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 91 96 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection
###end article-title 98
###begin article-title 99
Clinical pharmacokinetics of interferons
###end article-title 99
###begin article-title 100
###xml 43 60 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications
###end article-title 100
###begin article-title 101
Inactivation of interferon by serum and synovial fluids
###end article-title 101
###begin article-title 102
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human monocytes represent a competitive source of interferon-alpha in peripheral blood
###end article-title 102
###begin article-title 103
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells
###end article-title 103
###begin article-title 104
###xml 59 65 <span type="species:ncbi:9606">people</span>
###xml 92 97 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1
###end article-title 104
###begin article-title 105
Interferons, Mx genes, and resistance to influenza virus
###end article-title 105
###begin article-title 106
###xml 70 75 <span type="species:ncbi:9606">human</span>
###xml 87 114 <span type="species:ncbi:10298">herpes simplex virus type 1</span>
Activation of cellular interferon-responsive genes after infection of human cells with herpes simplex virus type 1
###end article-title 106
###begin article-title 107
Strong transient expression of the type I interferon-induced MxA protein in hepatitis A but not in acute hepatitis B and C
###end article-title 107

